40. The composition of claim 18, wherein said antibody blocks binding of IL-11 to a human IL-11 receptor.

41. The composition of claim 18, wherein said antibody is a polyclonal antibody.

42. The composition of claim 18, wherein said antibody is a monoclonal antibody.

43. The composition of claim 18, wherein said antibody specifically reacts with a human IL-11R protein comprising the amino acid sequence of SEQ ID NO:2.

44. The composition of claim 18, wherein said antibody specifically reacts with a human IL-11R protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 422.

45. The composition of claim 18, wherein said antibody specifically reacts with a human IL-11R protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 365.

46. The composition of claim 18, wherein said antibody specifically reacts with a human IL-11R protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 391 to 422.

47. The composition of claim 18, wherein said antibody specifically reacts with a human IL-11R protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 102 to 422.

48. The composition of claim 18, wherein said antibody specifically reacts with a human IL-11R protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 102 to 365.

49. The composition of claim 18, wherein said antibody specifically reacts with a human IL-11R protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 359.

50. The composition of claim 18, wherein said antibody specifically reacts with a human IL-11R protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 345.

51. The composition of claim 18, wherein said antibody specifically reacts with a human IL-11R protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 324.

52. The composition of claim 18, wherein said antibody is obtained using as an immunogen a human IL-11R protein with a cysteine residue at the carboxyl terminus.

53. The composition of claim 18, wherein said antibody is obtained using as an immunogen a human IL-11R protein with tyrosine residues replaced with sulfated tyrosine residues.

54. The composition of claim 18, wherein said antibody specifically reacts with a human IL-11R protein conjugated to a hapten.

55. The composition of claim 18, wherein said antibody obtained using as an immunogen a human IL-11R protein conjugated to a hapten.

56. The composition of claim 55, wherein hapten is keyhole limpet hemocyanin (KLH).

57. A pharmaceutical composition comprising the composition of claim 18 and a pharmaceutically acceptable carrier.

58. A composition comprising a neutralizing monoclonal antibody that binds specifically to an IL-11R protein, wherein said neutralizing antibody blocks binding of IL-11 to a human IL-11 receptor.